FindTrial
Sign In

EFFICACY OF NEBULIZED MAGNESIUM SULPHATE AS A BRONCHODILATOR IN CLINICALLY DIAGNOSED CASES OF BRONCHIOLITIS (mostly due to viral infection in 2m to 2yr children characterised by fever, cough, wheezing, tachpynea, retractions and respiratory distress.)

EFFICACY OF NEBULIZED MAGNESIUM SULPHATE AS A BRONCHODILATOR IN CLINICALLY DIAGNOSED CASES OF BRONCHIOLITIS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/040848
Enrollment
150
Registered
2022-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J219- Acute bronchiolitis, unspecified

Interventions

Intervention1: magnesium sulphate: 40mg/kg of magnesium sulfate will be given as nebulisation 3doses at 20min interval and then every 4hourly upto 24 hours. Control Intervention1: Epinephrine: 0.1ml/k

Sponsors

AFMRC PROJECT
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 150 infants and children between the ages of 2 months to 2 years with clinical diagnosis of acute bronchiolitis will be included in this study.

Exclusion criteria

Exclusion criteria: Children with congenital heart disease, congenital lung anomalies, pneumonia, foreign body, those in respiratory failure, clinically diagnosed cases of asthma, infants mechanically ventilated in neonatal period will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
TO COMPARE BRONCHIOLITIS SEVERITY SCORE AND FIO2 REQUIREMENTTimepoint: AT ADMISSION,30MIN,1HR,3,6,12,24HRS—

Secondary

MeasureTime frame
TO SEE SIDEEFFECTS IF ANYTimepoint: AT ADMISSION,30MIN,1HR,3,6,12,24HRS—

Countries

India

Contacts

Public ContactBHUPENDER SINGH

7AIRFORCE HOSPITAL

drbhupendersingh1976@gmail.com9632579980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026